Minimum Power and Frequency of Repeated Low-level Red-light to Effectively Control Myopia Progression

Launched by SHANGHAI EYE DISEASE PREVENTION AND TREATMENT CENTER · Nov 29, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how low-level red light therapy can help slow down the progression of myopia, commonly known as nearsightedness, in children aged 8 to 10 years old. The researchers want to find out the least amount of power and frequency of this red light treatment needed to be effective. They will also study what happens to children’s vision after stopping the treatment to see if there’s any rebound effect.

To participate in this study, children must be between 8 and 10 years old and have low myopia, meaning their vision is slightly blurry at a distance. They should not have any serious eye conditions or previous eye surgeries. If your child joins, they will receive the red light treatment and have regular check-ins with the study team to monitor their vision. This trial is currently recruiting, so it’s a great opportunity for families looking for new ways to manage myopia in their children.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age: 8-10 years old
• • 2. Low myopia: cycloplegic spherical equivalent refractions (SERs) range from -0.50 (inclusive) to -3.00 diopters (D) and astigmatism less than -2.5 D in either eye.
• • 3. signed informed consent and was able to participate in the study
• Exclusion Criteria:
• • 1. Secondary myopia, such as a history of retinopathy of prematurity or other neonatal diseases; syndromic myopia with a known genetic disorder or connective tissue disease, such as Stickler syndrome or Marfan syndrome
• • 2. Strabismus or other binocular vision abnormalities
• • 3. Cloudy refractive media: cloudy cornea, cataract or intraocular lens surgery
• • 4. Eye diseases that affect retinal function: macular degeneration, diabetic retinopathy, retinal detachment, glaucoma or ocular hypertension, endophthalmitis, uveitis, optic neuropathy, etc.
• • 5. History of refractive surgery, internal eye surgery, laser therapy, vitreous injection, etc.
• • 6. diabetes, hypertension and other systemic disorders
• • 7. History of use of retinal toxic drugs, such as hydroxychloroquine, etc.
• • 8. Use of orthokeratology, atropine, multifocal frame glasses and other myopia control methods; children who are currently receiving atropine, orthokeratology, multifocal frame glasses and other myopia control treatment, can be enrolled after 2 weeks of treatment.
• • 9. Other reasons considered unsuitable for inclusion by the study physician, including but not limited to other ocular and systemic disease abnormalities